Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,953 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brain invasion by an otherwise benign meningioma in a cat.
Arai K, Nakamura S, Matsubara K, Ozaki Y, Kadekaru S, Sugiyama A, Mitsui I, Akashi N, Yoshitake R, Kutara K. Arai K, et al. JFMS Open Rep. 2024 Dec 16;10(2):20551169241291842. doi: 10.1177/20551169241291842. eCollection 2024 Jul-Dec. JFMS Open Rep. 2024. PMID: 39691674 Free PMC article.
Partial anomalous pulmonary venous connection in a dog.
Sugimoto K, Arai K, Mochizuki Y, Akashi N, Yoshitake R, Kutara K. Sugimoto K, et al. Among authors: arai k. J Small Anim Pract. 2024 Oct;65(10):780. doi: 10.1111/jsap.13761. Epub 2024 Jul 4. J Small Anim Pract. 2024. PMID: 38961764 No abstract available.
Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis.
Kimura M, Nishikawa T, Shimakami T, Terashima T, Horii R, Fukuda M, Yoshita M, Takata N, Hayashi T, Funaki M, Nio K, Takatori H, Arai K, Yamashita T, Honda M, Tanaka J, Kaneko S, Yamashita T. Kimura M, et al. Among authors: arai k. Glob Health Med. 2024 Dec 31;6(6):404-415. doi: 10.35772/ghm.2024.01008. Glob Health Med. 2024. PMID: 39741996 Free PMC article.
Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Ishihara N, Komatsu S, Yano Y, Fujishima Y, Ishida J, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Matsuura T, Tada T, Kodama Y, Fukumoto T. Ishihara N, et al. Among authors: arai k. Anticancer Res. 2025 Jan;45(1):251-260. doi: 10.21873/anticanres.17412. Anticancer Res. 2025. PMID: 39740814
2,953 results